目的 研究福辛普利聯(lián)合依帕司他片治療糖尿病腎病的療效。方法 選擇2016年1月-2017年12月新疆喀什第三師醫(yī)院收治的60例糖尿病腎病患者，隨機分為兩組。對照組口服依帕司他片治療，每次50 mg，每天3次。觀察組聯(lián)合口服福辛普利鈉片，每次20 mg，每天1次。兩組均治療4周。比較兩組的療效以及治療前后的腎功能、氧化應激指標改變情況。結果 觀察組的有效率為86.67%，顯著高于對照組的70.00%（P<0.05）。治療后，兩組患者的尿素氮（BUN）、24 h尿蛋白和血肌酐（Scr）均較治療前顯著降低（P<0.05），且觀察組顯著低于對照組（P<0.05）。治療后兩組的丙二醛（MDA）值較治療前顯著降低（P<0.05），總抗氧化能力（T-AOC）和超氧化物歧化酶（SOD）水平均較治療前顯著升高（P<0.05），且觀察組顯著優(yōu)于對照組（P<0.05）。結論 福辛普利聯(lián)合依帕司他片在減少糖尿病腎病患者全身氧化應激、改善腎功能方面均具有積極作用，可顯著提高療效，值得應用推廣。

Objective To investigate the effect of Epalrestat Tablets combined with fosinopril in treatment of diabetic nephropathy. Methods Selected 60 cases of patients with diabetic nephropathy who were treated in our hospital from January 2016 to December 2017, divided into two groups randomly. The control group was treated with Epalrestat Tablets alone, and the observation group combined with oral Phu Simpson Leigh treatment. The curative effects of two groups were compared, and the changes of renal function and oxidative stress index before and after treatment were compared. Results The effective rate of the observation group was significantly higher than control group (P<0.05). After treatment, BUN, 24-hour urinary protein and SCR in both groups were significantly decreased (P<0.05), and those in the observation group were significantly lower (P<0.05). After treatment, MDA values in both groups were significantly decreased (P<0.05), T-AOC and SOD values were significantly increased (P<0.05), especially in the observation group (P<0.05). Conclusion Epalrestat tablets combined with fosinopril have positive effects on reducing systemic oxidative stress and improving renal function in patients with diabetic nephropathy, which can significantly improve the curative effect.

R969.4